Leigh Pusey - Eli Lilly President
| LILY34 Stock | BRL 165.13 2.32 1.42% |
President
Ms. Leigh Ann Pusey is Senior Vice President Corporationrationrate Affairs and Communications of the Company. She first joined AIA in December 1996 as senior vice president for public affairs. She then served as chief operating officer and senior vice president of government affairs before being elevated to president and CEO in February 2009, succeeding former Montana governor Marc Racicot and becoming one of the few women to head a major insurance organization. AIA represents more than 325 insurers. Prior to joining AIA, Pusey had been the deputy assistant to President George H.W. Bush for the White House Office of Public Liaison, communications coordinator for U.S. House Speaker Newt Gingrich, and deputy director of communications for the Republican National Committee. since 2017.
| Age | 60 |
| Tenure | 7 years |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has return on total asset (ROA) of 0.1148 % which means that it generated a profit of $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6464 %, meaning that it generated $0.6464 on every $100 dollars invested by stockholders. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Lori Johnston | Amgen Inc | 54 | |
| Angela Hwang | Pfizer Inc | 57 | |
| Jonathan Graham | Amgen Inc | 62 | |
| David Piacquad | Amgen Inc | 62 | |
| John Young | Pfizer Inc | 58 | |
| Murdo Gordon | Amgen Inc | 56 | |
| Peter Griffith | Amgen Inc | 64 | |
| David Reese | Amgen Inc | 56 | |
| Esteban Santos | Amgen Inc | 55 | |
| Douglas Lankler | Pfizer Inc | 57 | |
| Cynthia Patton | Amgen Inc | 57 | |
| Lidia Fonseca | Pfizer Inc | 54 | |
Management Performance
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Alonzo Weems, VP Officer | ||
| Jacob Naarden, CEO VP | ||
| Diogo Rau, VP Officer | ||
| Donald Zakrowski, Chief Fin | ||
| Anat Ashkenazi, VP CFO | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Martin MIBS, VP Projects | ||
| Anat JD, Gen VP |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 1.91 T | |||
| Shares Outstanding | 28.51 B | |||
| Price To Earning | 41.09 X | |||
| Price To Book | 34.13 X | |||
| Price To Sales | 60.93 X | |||
| Revenue | 28.54 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Eli Stock
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.